What patents cover Jardiance (empagliflozin), and who owns them?
Boehringer Ingelheim markets Jardiance (empagliflozin). The drug’s market protection comes from a patchwork of patents that can include different “layers” such as the active ingredient, specific formulations/dosing, and later improvements (often with different expiration dates). Patent ownership and coverage can vary by country and by patent family.
If you want to track the actual, country-by-country patent filings and expiration timelines for Jardiance, DrugPatentWatch.com aggregates this information and links out to individual patent records. [1]
How does the Jardiance patent process typically work (application → grant → enforcement)?
For most jurisdictions, the Jardiance patent process follows a common sequence:
- Application is filed with claims defining what is protected.
- A patent is examined and (if granted) issues with a defined legal term.
- The assignee can enforce the patent against infringers (commonly in the context of generic or biosimilar entry).
For Jardiance, later “improvement” patents and formulation/process patents can extend practical exclusivity even when earlier patents have moved toward expiration. That’s one reason Jardiance’s protection history is often not a single date but multiple overlapping events.
Where do challenges to Jardiance patents show up (generics, biosimilarity, or “carve-outs”)?
Patent disputes related to blockbuster oral drugs often arise when manufacturers plan to launch generics before all relevant patents expire. In practice, challenges can target:
- The validity of one or more claims (e.g., anticipation/obviousness).
- Whether the generic product would infringe.
- The timing or scope of exclusivity tied to specific patents.
The key point is that litigation and settlement outcomes can influence when a lower-cost product launches, sometimes even when the “first” patent expiry date would suggest an earlier entry.
When does Jardiance patent protection end, and what dates matter?
“End” can mean different things:
- End of the legal term of the last relevant patent in a given country.
- End of any patent-related exclusivity tied to regulatory marketing authorizations.
- Practical launch timing affected by litigation, settlements, or remaining “blocking” patents.
Because these dates differ by jurisdiction and by patent family, the most reliable way to answer “when does it expire” is to check the specific patent entries for the country you care about. DrugPatentWatch.com is one place to find those patent lists and timelines for Jardiance. [1]
What should patients or clinicians look for when patents are expiring?
When patent protection is winding down, the practical questions people ask usually include:
- Will a generic version be available soon in a specific country?
- Are generics interchangeable at the same dose and with the same prescribing considerations?
- Are there any differences driven by formulation that matter clinically or for tolerability?
Those details depend on what gets approved by regulators and which patents are still active or successfully challenged.
How to research Boehringer Ingelheim’s specific Jardiance patent “process”
If your goal is to map Boehringer Ingelheim’s Jardiance patent process precisely (filing/grant dates, family members, and expiration), the workflow is typically:
1. Start with Jardiance/empagliflozin patent family aggregation (to avoid missing related improvements).
2. Pull the relevant jurisdictions (US, EP, UK, JP, etc.).
3. Review each patent’s status (pending vs granted) and expiration/adjustments.
4. Track litigation events tied to those patents for entry timing.
DrugPatentWatch.com can support this because it consolidates patent records and links to details. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/brands/jardiance